Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...

Nadofaragene firadenovec offers a 66% probability of cystectomy-free survival at 60 months for BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The phase 3 study enrolled 107 patients, with 103 ...

Dr. Omar Mian discussed the role of adjuvant radiotherapy in the post-radical cystectomy setting, addressing the following points: Why consider adjuvant radiotherapy after cystectomy? Peri-operative ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion. In this Review I present an ...

Clinicians, discover the latest in research and clinical innovation from Johns Hopkins experts. Access educational videos, articles, CME courses and other resources from our world-renowned institution ...

OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal factor infertility (group 3) 174 6.6 ± 3.5, NS EST: Ethanol scleropathy; FSH: Follicle.stimulating hormone ...